# US 2010/0249169 A1 · Formulations for parenteral delivery of compounds and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0249169 A1
- Document ID: US20100249169A1
- Status: Published application
- Kind: A1
- Application number: 12/726,113
- Filed: 2010-03-17
- Published: 2010-09-30
- Earliest claimed: 2006-08-04
- Assignees: Wyeth
- Inventors: Syed M. Shah; Christian Ofslager; Mahdi B. Fawzi; Nataliya Bazhina
- Web page: https://patentgrep.com/patent/US20100249169A1

## CPC

- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 31/485: Morphinan derivatives, e.g. morphine, codeine
- A61K 47/02: Inorganic compounds
- A61K 47/183: {Amino acids, e.g. glycine, EDTA or aspartame}
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/10: Laxatives
- A61P 1/14: Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 1/18: for pancreatic disorders, e.g. pancreatic enzymes
- A61P 7/06: Antianaemics
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 13/00: Drugs for disorders of the urinary system
- A61P 17/00: Drugs for dermatological disorders
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 25/36: Opioid-abuse
- A61P 27/02: Ophthalmic agents
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 37/02: Immunomodulators
- A61P 39/00: General protective or antinoxious agents
- A61P 41/00: Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides formulations that achieve effective delivery of methylnaltrexone compositions. The provided formulations are useful for preventing, treating delaying, diminishing or reducing the severity of side effects resulting from use of analgesic opioids.

## Claims

### Claim at position 1

1-70. (canceled)

### Claim 71

A pharmaceutical composition comprising:
an aqueous solution of methylnaltrexone, or a pharmaceutically acceptable salt thereof, wherein the aqueous solution further comprises a calcium salt, a chelating agent, and a stabilizing agent that inhibits degradation of the methylnaltrexone in the solution into a compound of Formula (I),
at room temperature,
wherein the methylnaltrexone is methylnaltrexone bromide provided at a concentration of about 5 mg/mL to about 32 mg/mL.

### Claim 72 (depends on 71)

The pharmaceutical composition of claim 71, wherein the stabilizing agent is glycine, benzoic acid, citric acid, glycolic acid, lactic acid, malic acid, or maleic acid.

### Claim 73 (depends on 72)

The pharmaceutical composition of claim 72, wherein the stabilizing agent is glycine, provided at a concentration within the range of about 0.1 mg/mL to about 0.8 mg/mL.

### Claim 74 (depends on 73)

The pharmaceutical composition of claim 73, wherein the stabilizing agent is glycine-HCl.

### Claim 75 (depends on 71)

The pharmaceutical composition of claim 71, wherein the chelating agent is a calcium salt chelating agent provided at a concentration of about 0.1 mg/mL to about 1.0 mg/mL.

### Claim 76 (depends on 72)

The pharmaceutical composition of claim 72, wherein the chelating agent is a calcium salt chelating agent provided at a concentration of about 0.1 mg/mL to about 1.0 mg/mL.

### Claim 77 (depends on 73)

The pharmaceutical composition of claim 73, wherein the chelating agent is a calcium salt chelating agent provided at a concentration of about 0.1 mg/mL to about 1.0 mg/mL.

### Claim 78 (depends on 74)

The pharmaceutical composition of claim 74, wherein the chelating agent is a calcium salt chelating agent provided at a concentration of about 0.1 mg/mL to about 1.0 mg/mL.

### Claim 79 (depends on 71)

The pharmaceutical composition of claim 71, wherein the calcium salt chelating agent is calcium disodium ethylenediaminetetraacetic acid (EDTA).

### Claim 80 (depends on 72)

The pharmaceutical composition of claim 72, wherein the calcium salt chelating agent is calcium disodium ethylenediaminetetraacetic acid (EDTA).

### Claim 81 (depends on 73)

The pharmaceutical composition of claim 73, wherein the calcium salt chelating agent is calcium disodium ethylenediaminetetraacetic acid (EDTA).

### Claim 82 (depends on 74)

The pharmaceutical composition of claim 74, wherein the calcium salt chelating agent is calcium disodium ethylenediaminetetraacetic acid (EDTA).
